NTLA

Intellia Therapeutics, Inc. (NTLA) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Intellia Therapeutics is a clinical-stage gene editing company focused on developing CRISPR-based therapies for genetic diseases (in vivo) and immuno-oncology/autoimmune diseases (ex vivo). The company's lead programs are nex-z (for ATTR amyloidosis) and lonvo-z (for hereditary angioedema). In January 2025, the company executed a strategic restructuring, reducing its workforce by approximately 27% to prioritize high-value programs.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Q2 2025 revenue increased 105% year-over-year, driven primarily by cost reimbursements from the Regeneron collaboration. However, YTD revenue decreased 14% due to the recognition of $21.0 million in intra-entity profit from AvenCell in the prior year, which did not recur.
• Expenses: Total operating expenses decreased by $21.8 million in Q2 and $27.3 million YTD. This reduction is primarily attributable to a 27% workforce reduction in January 2025, resulting in lower employee-related expenses and a significant decrease in stock-based compensation ($11.4 million decrease in Q2).
• Investment Income: Other income improved significantly due to a $21.7 million decrease in expenses related to the change in fair value of investments compared to the prior year.
• Cash Flow: Net cash used in operating activities increased to $248.6 million YTD 2025 from $178.8 million YTD 2024. This increase includes approximately $65.0 million in non-recurring cash payments related to the strategic restructuring and real estate consolidation.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects current cash, cash equivalents, and marketable securities ($630.5 million) combined with collaboration funding to fund operations into the first half of 2027.
• Clinical Milestones:
  • Lonvo-z (HAE): Phase 3 HAELO study recruitment ended early; randomization expected to complete in Q3 2025. BLA submission targeted for H2 2026; potential launch in 2027.
  • Nex-z (ATTR): Phase 3 MAGNITUDE trial (ATTR-CM) enrollment is ahead of schedule, with plans to expand enrollment to ~1,200 patients. Phase 3 MAGNITUDE-2 (ATTRv-PN) enrollment expected to complete in H1 2026, supporting a BLA submission by 2028.
• Real Estate: The company entered a new lease for 400 Tech Square in Cambridge, with rent commencing in December 2026. A $78.0 million payment was made to modify/terminate the previous Waltham lease.
• Risks & Contingencies:
  • Litigation: Active patent infringement lawsuit by BlueAllele Corp. regarding bi-directional insertion template technology. Two stockholder lawsuits (Gonzalez and Aiello) filed in 2025 regarding disclosures and director compensation.
  • Regulatory: Risks associated with the novel nature of in vivo gene editing and potential changes in FDA guidance or staffing.

Investor Verification Checklist

• Runway Validation: Verify the $630.5 million cash balance against the projected burn rate to confirm the "first half of 2027" liquidity estimate.
• Restructuring Costs: Confirm the total one-time cash outflow ($65 million) and the remaining accrued severance liabilities ($1.0 million) to assess future cash impact.
• Regeneron Revenue: Review the specific terms of cost reimbursements and milestone payments to understand the sustainability of the Q2 revenue spike.
• Lease Obligations: Assess the long-term impact of the new Tech Square lease ($108/sq ft base rent) on future operating expenses starting in late 2026.
• Legal Exposure: Monitor the status of the BlueAllele patent litigation and the two stockholder derivative/class action suits for potential financial or operational disruption.